Alembic Pharma Q1FY24 Results: Consolidated PAT of Rs. 120.60 Cr

Alembic Pharma Q1FY24 Results: Consolidated PAT of Rs. 120.60 Cr

Alembic Pharma Q1 results show revenue up from 1407.34 crores to 1497.81 crores, a 6.43% increase in growth. EPS down from ₹7.76 to ₹6.14, down by -20.88%.

First, Let’s Begin with Quarter-on-Quarter Basis:

Alembic Pharma shared its Q1 results on Friday. They earned 1497.81 crores in revenue this quarter, but that’s more than the 1407.34 crores they made last quarter. The company’s growth increased by 6.43 percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 120.60 crores, down from 152.60 crores in the previous quarter. Their quarter-to-quarter growth decreased by -20.97 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹6.14, which is a decrease of -20.88% from the ₹7.76 EPS in the previous quarter.

Now, Let’s Analyze the Results on a Year-over-Year Basis:

The company made a total revenue of 1497.81 crores this year (2023), which is 18.57 percent higher than last year’s total revenue of 1263.22 crores.

This year’s PAT (Profit After Tax) is 120.60 crores, which is also 283.06% higher than last year’s PAT of -65.88 crores.

The EPS (Earnings Per Share) for this year is ₹6.14, which is 283.28% more than the EPS of ₹-3.35 earned last year.

Also Read: IDFC Q1FY24 Results: Consolidated PAT of Rs. 264.15 Cr

Alembic Pharma Share Dividend Announcement / Record Date:

The record date for the dividend has not arrived yet.

About Alembic Pharma:

Alembic Pharmaceuticals Ltd. is a prominent Indian multinational pharmaceutical company with its headquarters situated in Vadodara. The company is primarily engaged in the manufacturing of pharmaceutical products, pharmaceutical substances, and intermediates. It has earned the reputation of being a market leader in the macrolides segment of anti-infective drugs in India.

Download the Full PDF of Alembic Pharma Q1 Results: Click Here

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *